Binds A Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 435/337)
  • Patent number: 10617764
    Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 14, 2020
    Assignee: GENMAB A/S
    Inventors: Jesper Valbjørn, Xiaona Jing, Kelly Ann Roby, Timothy Warren Paul, Gregory Allan Sacha, Nathan Alan Pease, Bodil Willumsen
  • Patent number: 10385121
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 20, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Patent number: 9688776
    Abstract: Disclosed herein is an anti-migis-??antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes. Disclosed further is a pharmaceutical composition comprising the anti-migis-? antibody and a pharmaceutically acceptable carrier. Disclosed further is a method for lysing mIgA-expressing B lymphocytes and reducing IgA production in a human subject in vivo by employing an antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: June 27, 2017
    Inventors: Tse-Wen Chang, Alfur Fu-Hsin Hung, Donic Chien-Sheng Lu
  • Patent number: 9492565
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 15, 2016
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Patent number: 9168314
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 27, 2015
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Publication number: 20150099298
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
  • Publication number: 20150093395
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Andras Gruber, Erik I. Tucker, David Gailani
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8962819
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Adienne S.A.
    Inventors: Francesco Tedesco, Roberto Marzari
  • Patent number: 8940489
    Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: January 27, 2015
    Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
  • Patent number: 8940883
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: January 27, 2015
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, David Gailani
  • Patent number: 8907072
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • Publication number: 20140349323
    Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 27, 2014
    Inventors: Ulrich Essig, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Publication number: 20140302033
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 9, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
  • Publication number: 20140295494
    Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 2, 2014
    Applicant: TANOX, INC.
    Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
  • Patent number: 8809508
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: August 19, 2014
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Patent number: 8795999
    Abstract: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: August 5, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Barbara Plaimauer, Gerhard Antoine
  • Publication number: 20140199361
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 17, 2014
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Publication number: 20140186365
    Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 3, 2014
    Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Oncobiologics, Inc.
    Inventors: Matthew K. Robinson, John K. Cini, Jimson W. D'Souza
  • Patent number: 8759293
    Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: June 24, 2014
    Assignee: Grifols Therapeutics Inc.
    Inventor: Thomas Barnett
  • Publication number: 20140162356
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: January 16, 2014
    Publication date: June 12, 2014
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Patent number: 8728740
    Abstract: Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 20, 2014
    Assignee: Sirius-Biotech S.R.L.
    Inventors: Patrizia Castellani, Francesca Sassi, M. Barbara Carnemolla, Laura Borsi, Enrica Balza
  • Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Patent number: 8715951
    Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: May 6, 2014
    Assignee: The University of Vermont and State Agriculture College
    Inventors: Behnaz Parhami-Seren, Kenneth G. Mann, David N. Fass
  • Patent number: 8716031
    Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 6, 2014
    Assignees: RIKEN, Animal Allergy Clinical Laboratories
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Nobutaka Yasuda
  • Patent number: 8614306
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: December 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Patent number: 8501427
    Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: August 6, 2013
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
  • Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Publication number: 20130129745
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 23, 2013
    Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Oregon Health & Science University, Vanderbit University
  • Patent number: 8399648
    Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 19, 2013
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
  • Patent number: 8388959
    Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 5, 2013
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, David Gailani
  • Publication number: 20130052685
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Publication number: 20130052202
    Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 27, 2012
    Publication date: February 28, 2013
    Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
  • Patent number: 8383802
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: February 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
  • Patent number: 8372403
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: February 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Patent number: 8367356
    Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: February 5, 2013
    Assignee: Beijing Cotimes Biotech Co., Ltd.
    Inventors: Enyun Shen, Zheng Yu, Min Zhou, Fei Guo
  • Publication number: 20130011869
    Abstract: Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 10, 2013
    Applicant: Mitsubishi Chemical Medience Corporation
    Inventors: Yutaka Nagahama, Junko Nozaki, George Sakurai
  • Patent number: 8343493
    Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: January 1, 2013
    Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), Sanofi
    Inventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
  • Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • Publication number: 20120148571
    Abstract: The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Application
    Filed: July 18, 2011
    Publication date: June 14, 2012
    Applicant: Ablynx N.V.
    Inventors: Ignace Joseph Isabella Lasters, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Patent number: 8198407
    Abstract: The invention discloses methods for sequential protein isolation and purification from a biological sample by affinity chromatography. Affinity chromatography is conducted using ligands or ligand support complexes that selectively and specifically bind to proteins in the biological sample. The ligands or ligand support complexes were contacted sequentially in a predetermined order with the biological sample to allow each ligand or ligand-support complex to sequentially bind a protein from the biological sample.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 12, 2012
    Assignees: Prometic Biosciences, Ltd., The American National Red Cross
    Inventors: Steven J. Burton, Baldev Baines, John Curling, Christopher Bryant, David John Hammond, Dwun-Hou Chen, Timothy Keith Hayes
  • Patent number: 8193329
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: June 5, 2012
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Publication number: 20120114647
    Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: July 14, 2010
    Publication date: May 10, 2012
    Inventors: Edward Coulstock, Elena De Angelis, Haiqun Liu, Oliver Schon
  • Publication number: 20110300156
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 9, 2009
    Publication date: December 8, 2011
    Applicant: GENMAB A/S
    Inventors: Sandra Verploegen, David P.E. Satijn, Rene Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Patent number: 7993644
    Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: August 9, 2011
    Assignee: Purdue Pharma L.P.
    Inventor: Baiyang Wang
  • Patent number: 7915004
    Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: March 29, 2011
    Assignee: Farma Development S.r.l.
    Inventors: Alberto Mantovani, Giuseppe Peri
  • Patent number: 7846673
    Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: December 7, 2010
    Assignee: Institute of Virology of the Slovak Academy of Sciences
    Inventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova
  • Patent number: 7829294
    Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: November 9, 2010
    Assignee: Daiichi Pure Chemicals Co., Ltd.
    Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
  • Patent number: 7829095
    Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: November 9, 2010
    Assignee: CSL Behring GmbH
    Inventors: Juergen Roemisch, Wiegand Lang, Annette Feussner, Gudrun Muth-Naumann, Hans-Arnold Stoehr, Christian Kannemaier, Klaus Preissner, Fumie Nakazawa
  • Patent number: 7785898
    Abstract: The present invention provides methods for identifying and/or enriching fetal cells from maternal blood, using as fetal cell markers the antibodies that the mother produces against paternally inherited fetal antigens. The fetal cell-maternal antibody complexes are identified and isolated using labelled agents that bind to the maternal antibodies. The present invention also provides fetal cells, isolated by use of said maternal antibodies, as a source of fetal DNA for prenatal genetic diagnosis of the fetus.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: August 31, 2010
    Assignee: Genetic Technologies Limited
    Inventor: Ralph M. Bohmer